Minority outreach pairs docs, clergy

Share this article:
A triumvirate of companies is seeking pharma sponsors for a disease awareness campaign centered on Black churches.

The campaign, called the Minority Outreach Initiative and run by Healthy National Network, Roska Healthcare Advertising and Impact Health, would stage or promote health screenings at Black churches, with a focus on chronic diseases that impact African Americans disproportionately: diabetes, obesity, cancer, cardiovascular disease,   HIV/Aids and asthma. The effort would connect Black pastors and faith-based organizations with key physician opinion leaders in their communities, educating doctors, clergy and their parishoners alike on disease states.

Those testing as at-risk for a disease would receive on-the-spot counseling, with the option to set up a doctor’s appointment then and there and to enroll in relationship marketing programs. 

“It’s really convenient on a Sunday, when most people are there for services anyway,” says David Comey, founder and managing director of HNN.

The unbranded campaign would be promoted through the National Medical Association, an organization of Black physicians. “What we’re trying to do is to connect the dots,” says Jay Bolling, president of Roska. “Access in many of these communities is really fractured.” 
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...